|
[1]
|
Vineis, P. and Wild, C.P. (2014) Global Cancer Patterns: Causes and Prevention. Lancet, 383, 549-557. [Google Scholar] [CrossRef]
|
|
[2]
|
王丹霞, 全文婕, 史晓欣, 等. 肝癌早期诊断标志物及其检测方法的研究进展[J]. 肿瘤药学, 2016, 6(1): 15-20.
|
|
[3]
|
Yu, L.X. and Schwabe, R.F. (2017) The Gut Microbiome and liver Cancer: Mechanisms and Clinical Translation. Nature Reviews Gastroenterology & Hepatology, 14, 527-539. [Google Scholar] [CrossRef] [PubMed]
|
|
[4]
|
Ren, Z., et al. (2018) Gut Microbiome Analysis as a Tool towards Targeted Non-Invasive Biomarkers for Early Hepatocellular Carcinoma. Gut, gutjnl-2017-315084.
|
|
[5]
|
周进学. 基于肿瘤基因高通量捕获测序技术的肝癌分子分型研究[D]: [博士学位论文]. 郑州: 郑州大学, 2016.
|
|
[6]
|
Wooden, B., et al. (2017) Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases. Gastroenterology, 152, 53-67. [Google Scholar] [CrossRef] [PubMed]
|
|
[7]
|
Breuhahn, K., Gores, G. and Schirmacher, P. (2011) Strategies for Hepatocellular Carcinoma Therapy and Diagnostics: Lessons Learned from High Throughput and Profiling Approaches. Hepatology, 53, 2112-2121. [Google Scholar] [CrossRef] [PubMed]
|
|
[8]
|
邵雪. 基于HPLC/TripleTOF-MS/MS技术慢性乙型肝炎感染不同阶段的代谢组学研究[D]: [博士学位论文]. 长春: 吉林大学, 2012.
|
|
[9]
|
Takashima, M., et al. (2006) Proteomic Analysis of Autoantibodies in Patients with Hepatocellular Carcinoma. Proteomics, 6, 3894-3900. [Google Scholar] [CrossRef] [PubMed]
|
|
[10]
|
李克, 曹璐颖. 血清蛋白质组学技术在肿瘤血清标志物筛选中的应用[J]. 医学研究杂志, 2012, 41(9): 18-21.
|
|
[11]
|
Mustafa, M.Z., et al. (2016) Autoantibody Signatures Defined by Serological Proteome Analysis in Sera from Patients with Cholangiocarcinoma. Journal of Translational Medicine, 14, 17. [Google Scholar] [CrossRef] [PubMed]
|
|
[12]
|
同颖娜, 李丹. microRNA的液体芯片检测方法[J]. 分子诊断与治疗杂志, 2011, 3(3): 200-202.
|
|
[13]
|
梁惠仪, 彭娟, 李明, 等. 液体芯片技术定量测定人体血清CEA、AFP、NSE和tPSA [J]. 分子诊断与治疗杂志, 2010, 2(4): 266-271.
|
|
[14]
|
Chen, L., et al. (2010) Enhanced Detection of Early Hepatocellular Carcinoma by Serum SELDI-TOF Proteomic Signature Combined with Alpha-Fetoprotein Marker. Annals of Surgical Oncology, 17, 2518-2525. [Google Scholar] [CrossRef] [PubMed]
|
|
[15]
|
Lu, H.B., et al. (2010) Five Serum Proteins Identified Using SELDI-TOF-MS as Potential Biomarkers of Gastric Cancer. Japanese Journal of Clinical Oncology, 40, 336-342. [Google Scholar] [CrossRef] [PubMed]
|
|
[16]
|
Della, C.C., et al. (2016) Early Diagnosis of Liver Cancer: An Appraisal of International Recommendations and Future Perspectives. Liver International, 36, 166-176. [Google Scholar] [CrossRef] [PubMed]
|
|
[17]
|
Huang, T.S., et al. (2013) Diagnostic Performance of Alpha-Fetoprotein, Lens Culinaris Agglutinin-Reactive Alpha-Fetoprotein, Des-Gamma Carboxyprothrombin, and Glypican-3 for the De-tection of Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis Protocol. Systematic Reviews, 2, 37. [Google Scholar] [CrossRef] [PubMed]
|
|
[18]
|
梁广舒, 顾志冬. 脱-γ-羧基凝血酶原的基础和临床研究进展[J]. 诊断学理论与实践, 2016(5): 532-536.
|
|
[19]
|
Jiang, K., et al. (2016) Aberrant Expression of Golgi Protein 73 Is Indic-ative of a Poor Outcome in Hepatocellular Carcinoma. Oncology Reports, 35, 2141-2150. [Google Scholar] [CrossRef] [PubMed]
|
|
[20]
|
Maitra, A. and Thuluvath, P.J. (2004) GP73 and Liver Disease: A (Golgi) Complex Enigma. The American Journal of Gastroenterology, 99, 1096-1098. [Google Scholar] [CrossRef] [PubMed]
|
|
[21]
|
Ning, S., et al. (2012) Glypican-3, a Novel Prognostic Marker of Hepatocellular Cancer, Is Related with Postoperative Metastasis and Recurrence in Hepatocellular Cancer Patients. Molecular Biology Reports, 39, 351-357. [Google Scholar] [CrossRef] [PubMed]
|
|
[22]
|
Kandil, D., et al. (2007) Glypican-3 Immunocytochemistry in Liver Fine-Needle Aspirates: A Novel Stain to Assist in the Differentiation of Benign and Malignant Liver Lesions. Cancer, 111, 316-322. [Google Scholar] [CrossRef] [PubMed]
|
|
[23]
|
Pogribny, I.P. (2018) MicroRNAs as Biomarkers for Clinical Studies. Experimental Biology and Medicine (Maywood), 243, 283-290. [Google Scholar] [CrossRef] [PubMed]
|
|
[24]
|
Wen, Y., et al. (2015) Plasma miRNAs as Early Biomarkers for Detecting Hepatocellular Carcinoma. International Journal of Cancer, 137, 1679-1690. [Google Scholar] [CrossRef] [PubMed]
|
|
[25]
|
Vogtmann, E. and Goedert, J.J. (2016) Epidemiologic Studies of the Human Microbiome and Cancer. British Journal of Cancer, 114, 237-242. [Google Scholar] [CrossRef] [PubMed]
|
|
[26]
|
Wan, M. and El-Nezami, H. (2018) Targeting Gut Microbiota in Hepatocellular Carcinoma: Probiotics as a Novel Therapy. Hepatobiliary Surgery and Nutrition, 7, 11-20. [Google Scholar] [CrossRef] [PubMed]
|
|
[27]
|
刘珍, 邓天好, 尹抗抗, 等. 肝复方对原发性肝癌模型小鼠肠道菌群影响的实验研究[J]. 湖南中医杂志, 2017, 33(7): 167-169.
|
|
[28]
|
Qin, N., et al. (2014) Alterations of the Human Gut Microbiome in Liver Cirrhosis. Nature, 513, 59-64. [Google Scholar] [CrossRef] [PubMed]
|
|
[29]
|
Tozun, N. and Vardareli, E. (2016) Gut Microbiome and Gastrointestinal Cancer. Journal of Clinical Gastroenterology, 50, S191-S196. [Google Scholar] [CrossRef]
|
|
[30]
|
李可欣, 马浩然, 张男男, 等. 肠道菌群在肝癌中的作用研究进展[J]. 实用医学杂志, 2018(9): 1575-1578.
|
|
[31]
|
Rozeik, M.S., et al. (2017) Evaluation of CD44 and CD133 as Markers of Liver Cancer Stem Cells in Egyptian Patients with HCV-Induced Chronic Liver Diseases versus Hepatocellular Carcinoma. Electron Physician, 9, 4708-4717. [Google Scholar] [CrossRef] [PubMed]
|